Physician profile
Abhinav Sinha
NPI 1376764779
$1,304.59
in general payments reported to CMS, 2019-2025
22 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $41.61 · 2021: $231 · 2022: $257 · 2023: $141 · 2024: $105 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.23 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $242.71 | 2021-2024 | Verquvo, Belsomra |
| Novo Nordisk INC | $188.34 | 2021-2025 | Ozempic, Rybelsus |
| W. L. Gore & Associates, INC. | $175.00 | 2025 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Novartis Pharmaceuticals Corporation | $125.39 | 2021-2022 | |
| Amgen INC. | $74.88 | 2023-2025 | Repatha, Krystexxa, Otezla |
| Abbvie INC. | $64.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.40 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.04 | 2020-2025 | Relistor, Xifaxan |
| Abbott Laboratories | $42.63 | 2025 | I-Stat |
| Mannkind Corporation | $42.50 | 2025 | |
| Lilly USA, LLC | $39.26 | 2020-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.14 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.77 | 2021 | |
| Shield Therapeutics INC | $19.53 | 2023 | Accrufer |
| Ucb, INC. | $19.07 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.48 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.94 | 2021 | |
| Dexcom, INC. | $16.33 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $16.10 | 2020 | |
| Pfizer INC. | $15.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.81 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhinav Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.